1-6 of 6
D. Hossfeld
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer: Results of a Three-Arm Randomized Multicenter Trial Comparing Doxorubicin, Epirubicin and Mitoxantrone Each in Combination with Cyclophosphamide

Available to Purchase
Subject Area:
Oncology
E. Heidemann, B. Steinke, J. Hartlapp, K. Schumacher, K. Possinger, S. Kunz, E. Neeser, G.v. Ingersleben, D. Hossfeld, H. Caffier, R. Souchon, R. Waldmann, E. Blümner, J. Clark
Journal: Onkologie
Onkologie (1993) 16 (5): 344–353.
https://doi.org/10.1159/000218287
Published Online: 08 May 2009
View articletitled, Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer: Results of a Three-Arm Randomized Multicenter Trial Comparing Doxorubicin, Epirubicin and Mitoxantrone Each in Combination with Cyclophosphamide
Open the PDF for Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer: Results of a Three-Arm Randomized Multicenter Trial Comparing Doxorubicin, Epirubicin and Mitoxantrone Each in Combination with Cyclophosphamide in another window
Journal Articles

Randomized Clinical Trial Comparing Mitoxantrone with Epirubicin and with Doxorubicin, each Combined with Cyclophosphamide in the First-Line Treatment of Patients with Metastatic Breast Cancer

Available to Purchase
Subject Area:
Oncology
E. Heidemann, B. Steinke, J. Hartlapp, K. Schumacher, K. Possinger, S. Kunz, E. Neeser, G.v. Ingersleben, D. Hossfeld, R. Waldmann
Journal: Onkologie
Onkologie (1990) 13 (1): 24–27.
https://doi.org/10.1159/000216714
Published Online: 27 April 2009
View articletitled, Randomized Clinical Trial Comparing Mitoxantrone with Epirubicin and with Doxorubicin, each Combined with Cyclophosphamide in the First-Line Treatment of Patients with Metastatic Breast Cancer
Open the PDF for Randomized Clinical Trial Comparing Mitoxantrone with Epirubicin and with Doxorubicin, each Combined with Cyclophosphamide in the First-Line Treatment of Patients with Metastatic Breast Cancer in another window
Journal Articles

Alternativen und Weiterentwicklung der Therapie der akuten myeloischen Leukämie (AML) des Erwachsenen: Update der bundesdeutschen multizentrischen Studien

Available to Purchase
Subject Area:
Oncology
T. Büchner, D. Urbanitz, W. Hiddemann, P. Koch, H.-J. Pielken, R. Kuse, A. Mohr, G. Maschmeyer, H. Kreutzmann, F. Wendt, K. Straif, H.A. Vaupel, C. Aul, J. Fischer, W. Schneider, H.J. König, L. Demling, M. Walter, W.D. Ludwig, H. Rühl, H. Seibt, Ch. Anders, M.R. Nowrousian, W. Gassmann, H. Löffler, R. Mertelsmann, D. Hossfeld, A. Von Paleske, H.W. Pees, J. Schwamborn, P. Meusers, F. Overkamp, K.-P. Hellriegel, H.H. Fülle, H. Bartels, B. Emmerich, E. Lengfelder, R. Donhuijsen-Ant, A. Ho, K. Mainzer, B. Bonfert, H. Köppler, E. Thiel, G. Middelhoff, L. Nowicki, K.-H. Zurborn, W. Siegert, M. Planker, W. Augener, A. Heinecke
Journal: Onkologie
Onkologie (1987) 10 (1): 14–16.
https://doi.org/10.1159/000216360
Published Online: 24 April 2009
View articletitled, Alternativen und Weiterentwicklung der Therapie der akuten myeloischen Leukämie (AML) des Erwachsenen: Update der bundesdeutschen multizentrischen Studien
Open the PDF for Alternativen und Weiterentwicklung der Therapie der akuten myeloischen Leukämie (AML) des Erwachsenen: Update der bundesdeutschen multizentrischen Studien in another window
Journal Articles

Akute myeloische Leukämie (AML) des Erwachsenen: Weiterentwicklung der Therapie auf der Basis klinischer Phase-II- und Phase-III-Studien

Available to Purchase
Subject Area:
Oncology
T. Büchner, D. Urbanitz, W. Hiddemann, P. Koch, H.-J. Pielken, R. Kuse, A. Mohr, G. Maschmeyer, H. Kreutzmann, F. Wendt, K. Straif, H.A. Vaupel, C. Aul, J. Fischer, W. Schneider, H.J. König, L. Demling, M. Walter, W.D. Ludwig, H. Rühl, H. Seibt, Ch. Anders, M.R. Nowrousian, W. Gassmann, H. Löffler, G. Zeile, D. Hossfeld, A. von Paleske, H.W. Pees, J. Schwamborn, P. Meusers, F. Overkamp, K.-P. Hellriegel, H.H. Fülle, H. Bartels, B. Emmerich, E. Lengfelder, R. Donhuijsen-Ant, A. Ho, K. Mainzer, B. Bonfert, H. Köppler, E. Thiel, G. Middelhoff, L. Nowicki, K.-H. Zurborn, W. Siegert, M. Planker, W. Augener, A. Heinecke
Journal: Onkologie
Onkologie (1986) 9 (2): 83–91.
https://doi.org/10.1159/000215970
Published Online: 24 April 2009
View articletitled, Akute myeloische Leukämie (AML) des Erwachsenen: Weiterentwicklung der Therapie auf der Basis klinischer Phase-II- und Phase-III-Studien
Open the PDF for Akute myeloische Leukämie (AML) des Erwachsenen: Weiterentwicklung der Therapie auf der Basis klinischer Phase-II- und Phase-III-Studien in another window
Journal Articles

Adjuvant Radio-Chemotherapy with 5-Fluorouracil and Leucovorin in Stage II and III Rectal Cancer: 12 Months vs. 6 Months of Therapy. A Study of the Association for Medical Oncology of the German Cancer Society

Available to Purchase
Subject Area:
Oncology
G. Hartung, A. Kopp-Schneider, P. Diezler, E. Hagmüller, A. Baur, J. Weniger, C. Wojatshcek, N. Janssen, D. Hossfeld, H. Lindemann, T. Schnabel, L. Edler
Journal: Onkologie
Onkologie (2000) 23 (4): 334–339.
https://doi.org/10.1159/000027166
Published Online: 07 September 2000
View articletitled, Adjuvant Radio-Chemotherapy with 5-Fluorouracil and Leucovorin in Stage II and III Rectal Cancer: 12 Months vs. 6 Months of Therapy. A Study of the Association for Medical Oncology of the German Cancer Society
Open the PDF for Adjuvant Radio-Chemotherapy with 5-Fluorouracil and Leucovorin in Stage II and III Rectal Cancer: 12 Months vs. 6 Months of Therapy. A Study of the Association for Medical Oncology of the German Cancer Society in another window
Journal Articles

Alteration in Epirubicin Pharmacokinetics and Metabolism by Dexverapamil: Results from a Phase II Study in Patients with Metastatic Breast Cancer

Available to Purchase
Subject Area:
Oncology
K. Mross, N. Kröger, K. Herbst, G. Gastl, D. Hossfeld
Journal: Onkologie
Onkologie (1999) 22 (1): 35–40.
https://doi.org/10.1159/000026910
Published Online: 08 March 1999
View articletitled, Alteration in Epirubicin Pharmacokinetics and Metabolism by Dexverapamil: Results from a Phase II Study in Patients with Metastatic Breast Cancer
Open the PDF for Alteration in Epirubicin Pharmacokinetics and Metabolism by Dexverapamil: Results from a Phase II Study in Patients with Metastatic Breast Cancer in another window